MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research a...(that the pharmacokinetics of MAP0004 was...),Health

Date:7/16/2008

that the pharmacokinetics of MAP0004 was similar to that experienced by adults with healthy lungs as shown in an earlier Phase 1 study. No serious adverse events were reported. In addition, no clinically significant changes were observed in pulmonary function tests or mean IgE levels, a measure of systemic immune response.

About MAP0004

In another Phase 2 efficacy study presented last year, MAP0004 provided pain relief in as fast as ten minutes, with relief sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine.

The therapeutic agent in MAP0004 is dihydroergotamine (DHE), which has a long history of use as a safe and effective migraine treatment. Many headache specialists consider DHE administered by injection to be the standard of care in treating chronic migraine and debilitating migraines that last more than 72 hours. MAP Pharmaceuticals is seeking to expand the use of this compound to treat migraines early, non-invasively and with a fast onset of action.

MAP0004 is orally inhaled and self administered at home using the company's proprietary Tempo(R) inhaler, a novel pressurized metered dose inhaler that synchronizes the discharge of drug with the patient's breathing cycle. The Tempo inhaler can be optimized for each therapy based on desired delivery, and is designed to dispense drug in an efficient and consistent manner to minimize dose-to-dose differences in and between patients. The inhaler is convenient and easy to use, and contains a dose counter that can lock out after a maximum number of doses.

About Migraine

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States. It presents with recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. Most migraines last between four and 24 hours, but some last as long
'/>"/>

SOURCE MAP Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate